Evidence map›Paper›PMID 42030935›Full record

ArticleCell reports. Medicine2026

A ketogenic diet sensitizes pancreatic cancer to glutamine metabolism inhibitors.

Omid Hajihassani, Asael Roichman, Jacob A Boyer, Michal MacArthur, Ricardo Cordova, Alexander Loftus, Christina S Boutros, Jonathan J Hue, Parnian Naji, Soubhi Tahhan and 25 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

35 authors.

Omid HajihassaniCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA; Department of Surgery, Division of Surgical Oncology, University Hospitals, Cleveland Medical Center, Cleveland, OH, USA.
Asael RoichmanPrinceton University, Princeton, NJ, USA; Department of Chemistry, Princeton University, Princeton, NJ 08544, USA; The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel.
Jacob A BoyerPrinceton University, Princeton, NJ, USA; Ludwig Institute for Cancer Research, Princeton Branch, Princeton, NJ, USA.
Michal MacArthurPrinceton University, Princeton, NJ, USA; Department of Chemistry, Princeton University, Princeton, NJ 08544, USA.
Ricardo CordovaDepartment of Chemistry, Princeton University, Princeton, NJ 08544, USA; Ludwig Institute for Cancer Research, Princeton Branch, Princeton, NJ, USA.
Alexander LoftusDepartment of Surgery, Division of Surgical Oncology, University Hospitals, Cleveland Medical Center, Cleveland, OH, USA.
Christina S BoutrosDepartment of Surgery, Division of Surgical Oncology, University Hospitals, Cleveland Medical Center, Cleveland, OH, USA.
Jonathan J HueDepartment of Surgery, Division of Surgical Oncology, University Hospitals, Cleveland Medical Center, Cleveland, OH, USA.
Parnian NajiCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA; Department of Surgery, Division of Surgical Oncology, University Hospitals, Cleveland Medical Center, Cleveland, OH, USA.
Soubhi TahhanDepartment of Surgery, Division of Surgical Oncology, University Hospitals, Cleveland Medical Center, Cleveland, OH, USA.
Peter GallagherDepartment of Surgery, Division of Surgical Oncology, University Hospitals, Cleveland Medical Center, Cleveland, OH, USA.
William BeeganDepartment of Surgery, Division of Surgical Oncology, University Hospitals, Cleveland Medical Center, Cleveland, OH, USA.
Danyal ShahDepartment of Surgery, Division of Surgical Oncology, University Hospitals, Cleveland Medical Center, Cleveland, OH, USA.
James ChoiCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Nimat ManzoorCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Shihong LeiCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Christine KimCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Moeez RathoreDepartment of Surgery, Division of Surgical Oncology, University Hospitals, Cleveland Medical Center, Cleveland, OH, USA.
Ishan ShahCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Kevin LeboCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Helen ChengCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Anusha MudigondaCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Craig HunterPrinceton University, Princeton, NJ, USA; Department of Chemistry, Princeton University, Princeton, NJ 08544, USA; Lewis-Sigler Institute of Integrative Genomics, Princeton University, Princeton, NJ, USA.
Mehrdad ZareiCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Sydney AlibeckoffDepartment of Molecular and Integrative Physiology, University of Michigan School of Medicine, Ann Arbor, MI, USA.
Karen JiCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Hallie GraorCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA; Department of Surgery, Division of Surgical Oncology, University Hospitals, Cleveland Medical Center, Cleveland, OH, USA.
Masaru MiyagiCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Ali Vaziri-GoharDepartments of Cancer Biology and Surgery, Stritch School of Medicine, Loyola University Chicago, Chicago, IL 60153, USA.
Henri BrunengraberCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Rui WangCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA; Department of Surgery, Division of Surgical Oncology, University Hospitals, Cleveland Medical Center, Cleveland, OH, USA.
Peder J LundCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA; Department of Surgery, Division of Surgical Oncology, University Hospitals, Cleveland Medical Center, Cleveland, OH, USA; Department of Nutrition, Case Western Reserve University, Cleveland, OH, USA.
Luke D RothermelDepartment of Surgery, Division of Surgical Oncology, University Hospitals, Cleveland Medical Center, Cleveland, OH, USA.
Joshua D RabinowitzPrinceton University, Princeton, NJ, USA; Department of Chemistry, Princeton University, Princeton, NJ 08544, USA; Lewis-Sigler Institute of Integrative Genomics, Princeton University, Princeton, NJ, USA; Ludwig Institute for Cancer Research, Princeton Branch, Princeton, NJ, USA.
Jordan M WinterCase Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA; Department of Surgery, Division of Surgical Oncology, University Hospitals, Cleveland Medical Center, Cleveland, OH, USA. Electronic address: jordan.winter@uhhospitals.org.

Funding

TUMOR METABOLISM PROGRAMP30CA043703 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI Amar Desai · 1987 to 2026
$142.3M
Role of LRG1 in colorectal cancer tumorigenesisR37CA278982 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI Rui Wang · 2024 to 2026
$1.1M
NCI NIH HHS P30 CA043703NCI NIH HHS R37 CA278982
6 · The paper itself

Abstract

Pancreatic cancer is the third leading cause of cancer-related death in the United States. Current chemotherapy options provide limited benefits. Emerging evidence suggests that a ketogenic diet (KD) exerts anti-tumor effects by reprogramming tumor metabolism and revealing therapeutic vulnerabilities. Efforts to target glutamine metabolism-an essential pathway in many cancers-have shown promise in preclinical models, but clinical efficacy has remained limited. Here, we show that a KD increases tricarboxylic acid (TCA) cycle activity and elevates reliance on glutamine-related metabolites in murine pancreatic cancer models and in vitro under KD-mimicking conditions. This metabolic adaptation occurs in response to reduced glucose availability. We demonstrate that combining glutamine metabolism inhibitors, such as CB-839 or 6-diazo-5-oxo-L-norleucine (DON), with a KD leads to robust anti-tumor effects in preclinical models of pancreatic cancer. Thus, metabolic vulnerability induced by dietary intervention provides a rationale for combining glutamine-targeted therapies with a ketogenic diet in future clinical studies.

Indexed as

Diet, KetogenicGlutaminePancreatic NeoplasmsAnimalsBenzeneacetamidesCell Line, TumorCitric Acid CycleDiazooxonorleucineGlucoseHumansMiceThiadiazolesBenzeneacetamidesCB-839DiazooxonorleucineGlucoseGlutamineThiadiazoleschemotherapycombination therapyglutamine metabolismglutamine tracingketogenic dietketogenic diet mediapancreatic cancerPDAC nutrient fluxtargeted therapy

Identifiers

PMID42030935
PMCPMC13198290

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.